Progress in the oral treatment of type 2 diabetes: Update on DPP-IV inhibitors

Current Diabetes Reviews

Volumn 5, Issue 2, 2009, Pages 92-101

  Salvatore, Teresa ^a,b   Carbonara, Ornella ^a   Cozzolino, Domenico ^a   Torella, Roberto ^a   Sasso, Ferdinando C ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; METFORMIN PLUS SITAGLIPTIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; GLUCOSE;

ADD ON THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DEPRESSION; DOSE KIDNEY FUNCTION RELATION; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; GASTROINTESTINAL DISEASE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STOMACH EMPTYING; TREATMENT DURATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIGENS, CD26; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INCRETINS;

EID: 68349094168     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339909788166819     Document Type: Review

References (100)

1. Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept 2005; 128: 87-91.
2. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
3. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-82.
4. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63(2): 492-8.
5. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964; 2 (7349): 20-1.
6. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29(1): 46-52.
7. Vilsbóll T, Holst JJ. Incretin, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004; 47(3): 357-66.
8. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory poly-peptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91(1): 301-7.
9. Vilsbóll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002; 45(8): 1111-9.
10. Meier JJ, Gallwitz B, Kask B, et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 2004; 53(Suppl 3): S220-4.
11. Kjems LL, Holst JJ, Vólund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52(2): 380-6.
12. Ørskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991; 87: 415-23.
13. Vilsbóll T, Krarup T, Deacon CF, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50(3): 609-13.
14. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86(8): 3717-23
15. Eissele R, Göke R, Willemer S, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992; 22(4): 283-91.
16. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (1-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138(1): 159-66.
17. De León DD, Crutchlow MF, Ham J-Y, Stoffers DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 2006; 38(5-6): 845-59.
18. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140(11): 5356-63.
19. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000; 278(6): E1010-8.
20. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996; 271(3 Pt 1): E458-64.
21. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like-peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996; 318(2-3): 429-35.
22. Nauck MA, El-Ouaghlidi A, Homepesch M, Jacobsen J, Elbroend B. No impairment of hypoglycemia counterregulation via glucagon with N2211, a GLP-1 derivative, in subjects with type 2 diabetes. Diabetes 2003; 52: A128.
23. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38(4): 665-73.
24. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101(3): 515-20.
25. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 2001; 50(10): 2237-43.
26. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144(12): 5145-8.
27. Friedrichsen BN, Neubauer N, Lee YC, et al. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 2006; 188(3): 481-92.
28. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucogon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359(9309): 824-30
29. Thornberry NA, Weber AE. Discovery of Januvia® (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 2007; 7(6): 557-68
30. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214(3): 829-35.
31. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85(10): 3575-81.
32. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for the other glucagon-like peptides. Regul Pept 1995; 58(3): 149-56.
33. Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 2005; 48(4): 608-11.
34. Mentlein R, Dahms P, Grandt D, Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993; 49(2): 133-144.
35. Reinhold D, Bank U, Täger M, et al. DPIV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. Front Bio Sci 2008; 13: 2356-63.
36. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003; 82(2): 53-73
37. S̀edo A, Malík R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta 2001; 1550(2): 107-16.
38. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettiq WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999; 274(51): 36505-12.
39. Maes MB, Scharpé S, De Meester I. Dipeptidyl peptidase II (DPPII), a review. Clin Chim Acta 2007; 380(1-2): 31-49.
40. Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000; 267(20): 6140-650.
41. Ajami K, Abbott CA, McCaughan W, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization, and DPIV-like peptidase activity. Bichim Biophys Acta 2004; 1679(1): 18-28.
42. Busek P, Stremenova J, Šedo A. Dipeptidyl peptidase-IV enzymatic activity bearing molecules in human brain tumors - good or evil? Front Bio Sci 2008; 13: 2319-26.
43. Fatt RR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Bio Sci 2008; 13: 3648-60.
44. Van der Veken P, Haemers A, Augustyns K. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. Curr Top Med Chem 2007; 7(6): 621-35.
45. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97(12): 6874-9.
46. Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the entero-insular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004; 53(5): 1326-35.
47. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-704.
48. Kim SJ, Nian C, Doudet DJ, McIntosh CH. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 2008; 57(5): 1331-9.
49. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47(11): 1663-70.
50. Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007; 30(6): 1344-50.
51. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a rewiev of recent clinical trials. Curr Med Res Opin 2008; 24: 489-96.
52. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28(1): 55-72.
53. He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007; 47: 633-41.
54. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 2006; 57: 265-81.
55. Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007; 28(6): 315-22.
56. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV in healthy subjects: results from two randomized, doubleblind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78(6): 675-88
57. Chu XY, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3 organic anion transporting polypeptide 4C1 and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007; 321(6): 673-83.
58. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008; 10(7): 545-55.
59. Herman GA, Bergman A, Wagner J. Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic profile and the propensity for drug-drug interaction (abstract). Diabetologia 2006; 49(Suppl 1): A795
60. Johnson A, Winslow R. Focus on Health: Drug makers say FDA slows U.S. pipeline - Emphasis on safety, side effects grows; swing of pendulum? Wall Street J, 2008.
61. Villhauer EB, Brinkman JA, Naderi GB, et al. (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46(13): 2774-89.
62. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2008; 51(14): 4357.
63. Kim YB, Kopcho LM, Kirby MS, et al. Mechanism of Gly-PropNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch Biochem Biophys 2006; 445(1): 9-18.
64. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29(12): 2632-7.
65. Raz I, HanefeldM, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49(11): 2564-71.
66. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61(1): 171-80.
67. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman E. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30(8): 1979-87.
68. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drugnaive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39(3): 218-23.
69. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diab Res Clin Pract 2007; 76(1): 132-8.
70. Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008; 10(8): 675-82.
71. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30(2): 217-23.
72. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9(2): 175-85.
73. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med 2007; 24(9): 955-61.
74. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29 (12): 2638-43.
75. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9(5): 733-45.
76. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study. Clin Ther 2006; 28(10): 1556-68.
77. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10(10): 959-69.
78. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9(2): 194-205.
79. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27(12): 2874-80.
80. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30(4): 890-5.
81. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9(2): 166-74.
82. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008; 10(1): 82-90
83. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50(6): 1148-55.
84. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31(1): 30-5.
85. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29(9): 2137-9.
86. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008; 30(3): 499-512.
87. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes Metab 2008; 10(5): 376-86.
88. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and metanalysis. JAMA 2007; 298(2): 194-206.
89. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; 16(2): CD006739.
90. Ahren B, Pacini G, Schweizer A. Improved meal related beta-cell function and dynamic insulin sensitivity by the DPP-4 inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-40.
91. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90(1): 501-6.
92. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul Pept 1999; 85(1): 9-24.
93. Ohnuma K, Takahashi N, Yamochi T, Hosono O, Dang NH, Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Bio Sci 2008; 13: 2299-310.
94. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidas IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006; 3(3): 159-65.
95. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54(10): 2988-94.
96. Burkey BF, Hoffmann PK, Hassiapen U, Trappe J, Juedes M, Foley JE. Adverse effects of dipeptidyl peptidase 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008; 10(11): 10567-61.
97. Salvatore T, Carbonara O, Cozzolino D, Torella R, Sasso FC. Adapting the GLP-1-signaling system to the treatment of type 2 diabetes. Curr Diabetes Rev 2007; 3(1): 15-23.
98. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008; 11(4): 491-9.
99. Scheen AJ. Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes. Rev Med Liege 2007; 62: 217-21.
100. Ahrén B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007; 30(6): 1344-50.